Streetbeat News

Stock Prices

SPR

Trading of Spirit Aerosystems (SPR) shares has resumed.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 4:01 pm

INUV

Inuvo shares are trading lower following the announcement of disappointing Q4 financial results, which fell below market expectations.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 4:01 pm

PANW

ZS

Zscaler Inc (NASDAQ:ZS) shares fell in premarket trading despite reporting higher-than-expected sales and earnings for the fiscal second quarter. Analysts provided mixed reactions, with several raising their price targets due to the company's strong performance, while others expressed concerns about the deceleration in billings growth and competitive landscape. Zscaler's management raised their billings guidance for fiscal 2024, reflecting confidence in the company's growth trajectory despite macro challenges and a competitive market.

Portfolio Pulse from Priya Nigam

March 01, 2024 | 4:01 pm

AMD

INTC

MSFT

NVDA

QQQ

TQQQ

Microsoft Corp has launched DirectSR, a new Windows API designed to enhance AI-upscaling in games by leveraging technologies from Nvidia, AMD, and Intel. This API simplifies the development process by allowing game developers to use a single code path for various super-resolution technologies. The move is expected to improve gaming experiences across different hardware platforms. Additionally, Microsoft's recent layoffs and game cancellations were mentioned, alongside the performance of ProShares UltraPro QQQ and Invesco QQQ Trust, Series 1.

Portfolio Pulse from Anusuya Lahiri

March 01, 2024 | 4:01 pm

TXT

Over the past 15 years, Textron (NYSE:TXT) has produced an average annual return of 23.02%, outperforming the market by 8.66%. A $1000 investment in TXT 15 years ago would be worth $23,749.33 today. Textron's market capitalization currently stands at $17.18 billion.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 4:01 pm

SHLS

Shoals Technologies Gr (NASDAQ:SHLS) has been the subject of 12 analyst reviews over the past three months, showing a mix of bullish to bearish sentiments. The average 12-month price target is now $19.33, a 20.06% decrease from the previous $24.18. Analysts from firms like Goldman Sachs, Cantor Fitzgerald, and JP Morgan have lowered their price targets, reflecting adjustments to market conditions and company performance. Despite a positive revenue trend with a 47.77% growth rate as of September 30, 2023, SHLS faces challenges in market capitalization, ROE, and ROA, positioning below industry averages.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 4:01 pm

TRGP

Targa Resources (NYSE:TRGP) has delivered an average annual return of 19.21% over the past 5 years, outperforming the market by 6.38%. An investment of $100 in TRGP 5 years ago would be worth $238.54 today. The company currently has a market capitalization of $21.92 billion.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 4:01 pm

CERT

Certara (NASDAQ:CERT) received mixed analyst ratings with 4 indifferent ratings in the past three months. The average 12-month price target is $17.38, up from $15.00, indicating a 15.87% increase. Analysts from Jefferies, Leerink Partners, Barclays, and UBS have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Certara, a company specializing in biosimulation software for drug discovery and development, shows a revenue growth of 1.03% as of September 30, 2023, but has a net margin of -57.22% and an ROE of -4.56%.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 4:01 pm

NKTR

Nektar Therapeutics (NASDAQ:NKTR) is scheduled to release its quarterly earnings report on March 4, 2024, with an expected EPS of $-0.21. Despite beating the EPS estimate last quarter by $0.01, NKTR's stock dropped by 8.76% the following day. Historically, the company's earnings performance has led to mixed stock price reactions. Currently trading at $0.71, NKTR shares have declined by 49.2% over the last year, indicating a bearish outlook among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 4:00 pm

PCRX

Analysts have provided varied ratings for Pacira BioSciences (NASDAQ:PCRX) over the past three months, with a recent shift towards a more bullish stance. The average 12-month price target has been adjusted to $47.25, marking a 10.85% decrease. The company faces revenue challenges with a -2.11% decline over 3 months but exhibits strong financial health with exceptional net margin and ROE. Pacira BioSciences specializes in non-opioid pain management solutions, notably EXPAREL.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 4:00 pm